Zoetis Inc (NYSE:ZTS) shares are trading higher after the company reported first-quarter FY24 revenue of $2.19 billion, up 10% Y/Y on reported and 12% Y/Y on an operational basis, beating the consensus of $2.132 billion. Revenue in the U.S. segment was $1.2 billion, up 16% Y/Y. Sales of companion animal products increased by 25%, driven by growth in key franchises including Simparica Trio, flea, tick and heartworm combination product, key dermatology portfolio, including Apoquel and Cytopoint, and osteoarthritis (OA) pain products, Librela for dogs and Solensia for cats. Revenue in the International segment stood at $1.0 billion, rising by 3% on a reported basis and by ...